Dr. Howard Burris Discusses the mTOR Inhibitor Everolimus
Howard A. Burris, III, MD
Published Online: Wednesday, September 5, 2012
Howard A. "Skip" Burris, III, MD, chief medical officer and executive director, Drug Development Program, Sarah Cannon Research Institute in Nashville, Tennessee, discusses the mammalian target of rapamycin (mTOR) inhibitor everolimus (Afinitor) for patients with HER2-negative breast cancer.
Burris believes that the addition of everolimus to the endocrine therapy combination strategy is going to be very important for managing patients with breast cancer. A substantial uptake in its use in the clinic has already been observed, since the FDA approval in July.
Targeting mTOR has caused a great deal of enthusiasm and sparked new clinical trials, Burris explains. He adds that everolimus will likely be the go-to therapy for patients receiving aromatase inhibitors who have progressed slowly or have not experienced a visceral crisis.
As more research is conducted, Burris expects everolimus will eventually move forward in many sequences as its efficacy is demonstrated both in the clinic and trials.
Although the potential for next-generation sequencing of breast cancer tumors to improve treatment strategies is widely recognized, questions swirl about the optimal use of such increasingly available technologies in clinical practice for today’s patients.
A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression